Status: Recruiting
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
Participants needed: 226
Trial details
Phase: Phase 3Age: 19-70Biological sex: AllType: InterventionalSponsor: Green Cross WellbeingUpdated: Feb 25, 2026Locations: 1
Eligibility criteria
At the time of screening, 19 or 70 years [+3]
If you have the following disease [+31]